Cargando…

Initial Evaluation of Therapy Response after Adjuvant Radioiodine Therapy in Patients with Early-Stage Papillary Thyroid Cancer—Does Time Matter?

SIMPLE SUMMARY: In recent years, there has been a clear trend toward personalized therapy procedures in patients with thyroid cancer with the aim to avoid unnecessary overtreatment of patients and to ensure an improved quality of life. We confirmed that early diagnostic control at 6 months after ini...

Descripción completa

Detalles Bibliográficos
Autores principales:	Grawe, Freba, Cramm, Yuri, Fabritius, Matthias P., Ruebenthaler, Johannes, Koehler, Viktoria F., Ilhan, Harun, Bartenstein, Peter, Wenter, Vera, Todica, Andrei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833817/ https://www.ncbi.nlm.nih.gov/pubmed/35158769 http://dx.doi.org/10.3390/cancers14030501

Ejemplares similares

(18)F-FDG-PET/CT in Patients with Advanced, Radioiodine Refractory Thyroid Cancer Treated with Lenvatinib
por: Ahmaddy, Freba, et al.
Publicado: (2021)

Course of Disease and Clinical Management of Patients with Poorly Differentiated Thyroid Carcinoma
por: Grawe, Freba, et al.
Publicado: (2021)

Effects of the Minimal Extrathyroidal Extension on Early Response Rates after (Adjuvant) Initial Radioactive Iodine Therapy in PTC Patients
por: Ahmaddy, Freba, et al.
Publicado: (2020)

Primary presentation and clinical course of pediatric and adolescent patients with differentiated thyroid carcinoma after radioiodine therapy
por: Burgard, Caroline, et al.
Publicado: (2023)

The diagnostic challenge of coexistent sarcoidosis and thyroid cancer – a retrospective study
por: Wenter, Vera, et al.
Publicado: (2021)

Clinical impact of follicular oncocytic (Hürthle cell) carcinoma in comparison with corresponding classical follicular thyroid carcinoma
por: Wenter, Vera, et al.
Publicado: (2020)

Diagnostic performance of PET/CT in the detection of liver metastases in well-differentiated NETs
por: Grawe, Freba, et al.
Publicado: (2023)

Second Adjuvant Radioiodine Therapy after Reoperation for Locoregionally Persistent or Recurrent Papillary Thyroid Carcinoma
por: Cadena-Piñeros, Enrique, et al.
Publicado: (2022)

Incidental Finding of a PSMA-Positive Pancreatic Cancer in a Patient Suffering from a Metastasized PSMA-Positive Prostate Cancer
por: Sirtl, Simon, et al.
Publicado: (2021)

The assessment of left ventricular mechanical dyssynchrony from gated (99m)Tc-tetrofosmin SPECT and gated (18)F-FDG PET by QGS: a comparative study
por: Lehner, Sebastian, et al.
Publicado: (2021)

Adjuvant Radioiodine for Intermediate-Risk Papillary Thyroid Cancer—To Treat or Not to Treat
por: van Velsen, Evert F S, et al.
Publicado: (2023)

Detection of apoptosis by [(18)F]ML-10 after cardiac ischemia–reperfusion injury in mice
por: Fischer, Maximilian, et al.
Publicado: (2022)

Thyrotoxicosis and radioiodine therapy: Does the dose matter?
por: Collier, Andrew
Publicado: (2012)

Validation of the SSTR-RADS 1.0 for the structured interpretation of SSTR-PET/CT and treatment planning in neuroendocrine tumor (NET) patients
por: Grawe, Freba, et al.
Publicado: (2023)

Radioiodine adjuvant therapy in differentiated thyroid cancer: An update and reconsideration
por: Sun, Yu-qing, et al.
Publicado: (2022)

Nephroprotective effects of enalapril after [177Lu]-DOTATATE therapy using serial renal scintigraphies in a murine model of radiation-induced nephropathy
por: Ilhan, Harun, et al.
Publicado: (2016)

To Treat or Not to Treat: The Role of Adjuvant Radioiodine Therapy in Thyroid Cancer Patients
por: Carballo, Marilee, et al.
Publicado: (2012)

High RPMB predicts poor disease-free survival of male N1 papillary thyroid cancer after adjuvant radioiodine therapy
por: An, Ning, et al.
Publicado: (2022)

Influence of dosimetry method on bone lesion absorbed dose estimates in PSMA therapy: application to mCRPC patients receiving Lu-177-PSMA-I&T
por: Brosch-Lenz, Julia, et al.
Publicado: (2021)

Correction to: Influence of dosimetry method on bone lesion absorbed dose estimates in PSMA therapy: application to mCRPC patients receiving Lu-177-PSMA-I&T
por: Brosch-Lenz, Julia, et al.
Publicado: (2021)

Toxicity of a combined therapy using the mTOR-inhibitor everolimus and PRRT with [(177)Lu]Lu-DOTA-TATE in Lewis rats
por: Zellmer, Johannes, et al.
Publicado: (2020)

Patient-specific image-based bone marrow dosimetry in Lu-177-[DOTA(0),Tyr(3)]-Octreotate and Lu-177-DKFZ-PSMA-617 therapy: investigation of a new hybrid image approach
por: Gosewisch, Astrid, et al.
Publicado: (2018)

Comparison of somatostatin receptor expression in patients with neuroendocrine tumours with and without somatostatin analogue treatment imaged with [(18)F]SiTATE
por: Eschbach, Ralf S., et al.
Publicado: (2023)

3D Monte Carlo bone marrow dosimetry for Lu-177-PSMA therapy with guidance of non-invasive 3D localization of active bone marrow via Tc-99m-anti-granulocyte antibody SPECT/CT
por: Gosewisch, Astrid, et al.
Publicado: (2019)

Response to (225)Ac-PSMA-I&T after failure of long-term (177)Lu-PSMA RLT in mCRPC
por: Ilhan, Harun, et al.
Publicado: (2020)

Acute Myeloid Leukemia after Low-Dose Radioiodine Therapy for Papillary Thyroid Carcinoma
por: Alsaud, Arwa, et al.
Publicado: (2020)

Feasibility of Different Tumor Delineation Approaches for (18)F-PSMA-1007 PET/CT Imaging in Prostate Cancer Patients
por: Mittlmeier, Lena M., et al.
Publicado: (2021)

New Molecular Targeted Therapy and Redifferentiation Therapy for Radioiodine-Refractory Advanced Papillary Thyroid Carcinoma: Literature Review
por: Wong, Kai-Pun, et al.
Publicado: (2012)

Combined Scintigraphy and Tumor Marker Analysis Predicts Unfavorable Histopathology of Neuroblastic Tumors with High Accuracy
por: Fendler, Wolfgang Peter, et al.
Publicado: (2015)

Investigation of image-based lesion and kidney dosimetry protocols for (177)Lu-PSMA-I&T therapy with and without a late SPECT/CT acquisition
por: Resch, Sandra, et al.
Publicado: (2023)

Incidentally Detected Metachronous Malignancy in Patients of Papillary Carcinoma of Thyroid Posthigh-Dose Radioiodine Therapy
por: Mishra, Ayush, et al.
Publicado: (2023)

Quantitative myocardial perfusion SPECT/CT for the assessment of myocardial tracer uptake in patients with three-vessel coronary artery disease: Initial experiences and results
por: Lehner, Sebastian, et al.
Publicado: (2021)

Total Tumor Volume on (18)F-PSMA-1007 PET as Additional Imaging Biomarker in mCRPC Patients Undergoing PSMA-Targeted Alpha Therapy with (225)Ac-PSMA-I&T
por: Unterrainer, Lena M., et al.
Publicado: (2022)

The BRAF V600E mutation is a predictor of the effect of radioiodine therapy in papillary thyroid cancer
por: Ge, Junshang, et al.
Publicado: (2020)

Salvage PRRT with (177)Lu-DOTA-octreotate in extensively pretreated patients with metastatic neuroendocrine tumor (NET): dosimetry, toxicity, efficacy, and survival
por: Rudisile, S., et al.
Publicado: (2019)

Image-based dosimetry for (225)Ac-PSMA-I&T therapy using quantitative SPECT
por: Gosewisch, A., et al.
Publicado: (2020)

The clinical meaning of pre- and post-ablation thyroglobulin levels at first radioiodine therapy in patients with papillary thyroid cancer
por: Kim, Hee Kyung, et al.
Publicado: (2020)

Correlation of an Index-Lesion-Based SPECT Dosimetry Method with Mean Tumor Dose and Clinical Outcome after (177)Lu-PSMA-617 Radioligand Therapy
por: Völter, Friederike, et al.
Publicado: (2021)

Is radioiodine administration in patients with papillary thyroid multifocal microcarcinoma unnecessary?
por: Krčálová, Eva, et al.
Publicado: (2016)

Evaluation of the Efficacy of a Combined Treatment Using the mTOR-Inhibitor Everolimus and [177Lu]Lu-DOTA-TATE in Nude CD1 Mice with SSTR-Expressing Pancreatic AR42J Xenograft Tumors
por: Zellmer, Johannes, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jhd1vcjd6c3lkc9nutb9ujjn4a